menu
    • menu
    [{"orgOrder":0,"company":"Rappta Therapeutics","sponsor":"Novo Seeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"PTPA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Rappta Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Rappta Therapeutics \/ Novo Seeds","highestDevelopmentStatusID":"1","companyTruncated":"Rappta Therapeutics \/ Novo Seeds"},{"orgOrder":0,"company":"Rappta Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"RPT04402","moa":"PP2A","graph1":"Oncology","graph2":"Preclinical","graph3":"Rappta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rappta Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Rappta Therapeutics \/ SpringWorks Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Rappta Therapeutics

    Menu

    Rappta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rappta Therapeutics

                            Finland arrow
                            BioAsia
                            Not Confirmed

                            Rappta Therapeutics

                            Finland arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RPT04402

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : SpringWorks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rappta, SpringWorks Sign License Deal for PP2A Targeting Molecular Glue

                            Details : Under the exclusive license agreement, SpringWorks Therapeutics will be responsible for the global development and commercialization of RPT04402 for treating PP2A mutant uterine cancer.

                            Product Name : RPT04402

                            Product Type : Other Small Molecule

                            Upfront Cash : $13.0 million

                            January 13, 2025

                            Lead Product(s) : RPT04402

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : SpringWorks Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rappta Therapeutics

                            Finland arrow
                            BioAsia
                            Not Confirmed

                            Rappta Therapeutics

                            Finland arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Novo Seeds

                            Deal Size : $10.6 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Novo Seeds Co-Leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A Drugs

                            Details : Rappta has developed proprietary tools and a unique understanding of PP2A which allows it to therapeutically reactivate PP2A.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 13, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Novo Seeds

                            Deal Size : $10.6 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth